AR079551A1 - Anticuerpos anti-her3 y usos de los mismos - Google Patents
Anticuerpos anti-her3 y usos de los mismosInfo
- Publication number
- AR079551A1 AR079551A1 ARP100104773A ARP100104773A AR079551A1 AR 079551 A1 AR079551 A1 AR 079551A1 AR P100104773 A ARP100104773 A AR P100104773A AR P100104773 A ARP100104773 A AR P100104773A AR 079551 A1 AR079551 A1 AR 079551A1
- Authority
- AR
- Argentina
- Prior art keywords
- same
- her3 antibodies
- antibodies
- her3
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticuerpos ligantes de HER3 humano (anticuerpo anti-HER3) a método para su produccion, a composiciones farmacéuticas que contienen dichos anticuerpos, y a usos de los mismos. Acido nucleico, vector de expresion, célula huésped, método de tratamiento de cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09015831 | 2009-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR079551A1 true AR079551A1 (es) | 2012-02-01 |
Family
ID=42126432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100104773A AR079551A1 (es) | 2009-12-22 | 2010-12-20 | Anticuerpos anti-her3 y usos de los mismos |
Country Status (33)
Country | Link |
---|---|
US (4) | US8859737B2 (es) |
EP (1) | EP2516469B1 (es) |
JP (2) | JP5680671B2 (es) |
KR (2) | KR20120098911A (es) |
CN (1) | CN102822201B (es) |
AR (1) | AR079551A1 (es) |
AU (1) | AU2010335282B2 (es) |
BR (1) | BR112012015255A2 (es) |
CA (1) | CA2782571C (es) |
CL (1) | CL2012001649A1 (es) |
CO (1) | CO6551674A2 (es) |
CR (1) | CR20120284A (es) |
CY (1) | CY1117563T1 (es) |
DK (1) | DK2516469T3 (es) |
EC (1) | ECSP12011995A (es) |
ES (1) | ES2571226T3 (es) |
HK (1) | HK1175183A1 (es) |
HR (1) | HRP20160737T1 (es) |
HU (1) | HUE029026T2 (es) |
IL (1) | IL220162A (es) |
MA (1) | MA33892B1 (es) |
MX (1) | MX2012007340A (es) |
MY (1) | MY161909A (es) |
NZ (1) | NZ600262A (es) |
PE (1) | PE20121616A1 (es) |
PL (1) | PL2516469T3 (es) |
RS (1) | RS54795B1 (es) |
RU (1) | RU2560583C2 (es) |
SG (1) | SG181894A1 (es) |
SI (1) | SI2516469T1 (es) |
TW (1) | TWI421092B (es) |
UA (1) | UA107821C2 (es) |
WO (1) | WO2011076683A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
PE20120550A1 (es) * | 2009-04-07 | 2012-05-21 | Roche Glycart Ag | ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET |
KR20120098911A (ko) * | 2009-12-22 | 2012-09-05 | 로슈 글리카트 아게 | 항-her3 항체 및 이의 용도 |
MX348739B (es) | 2010-03-10 | 2017-06-27 | F Hoffmann-La Roche Ag * | Metodo para purificar soluciones de inmunoglobulina. |
ES2566602T3 (es) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 |
SI2606070T1 (sl) | 2010-08-20 | 2017-04-26 | Novartis Ag | Protitelesa za receptor 3 epidermalnega rastnega faktorja (HER3) |
ITRM20100577A1 (it) | 2010-11-02 | 2012-05-03 | Takis Srl | Immunoterapia contro il recettore erbb-3 |
US20120258073A1 (en) | 2011-02-10 | 2012-10-11 | Christian Gerdes | Immunotherapy |
US20150231238A1 (en) | 2011-03-15 | 2015-08-20 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to erbb pathway inhibitors |
DK2699602T3 (en) | 2011-04-19 | 2017-06-06 | Merrimack Pharmaceuticals Inc | BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES |
BR112014003598B1 (pt) | 2011-08-23 | 2022-05-31 | Roche Glycart Ag | Molécula de ligação de antígeno biespecífica, composição farmacêutica e uso da molécula de ligação de antígeno biespecífica |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
ES2694153T3 (es) * | 2011-09-30 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 y usos de los mismos |
US9828635B2 (en) | 2011-10-06 | 2017-11-28 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
BR112014012539B1 (pt) | 2011-11-23 | 2022-12-20 | Medimmune, Llc | Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo |
SG11201402510TA (en) | 2011-11-30 | 2014-06-27 | Genentech Inc | Erbb3 mutations in cancer |
ES2758433T3 (es) * | 2011-12-05 | 2020-05-05 | Novartis Ag | Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3) |
JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Her3阻害剤に関する診断及び治療 |
ES2848732T3 (es) | 2012-08-07 | 2021-08-11 | Roche Glycart Ag | Inmunoterapia mejorada |
AR094403A1 (es) * | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
WO2014114595A1 (en) | 2013-01-23 | 2014-07-31 | Roche Glycart Ag | Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
WO2014159915A1 (en) | 2013-03-14 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Her3 specific monoclonal antibodies for diagnostic and therapeutic use |
US20140271634A1 (en) | 2013-03-14 | 2014-09-18 | The Regents Of The University Of California | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
CN105121471A (zh) * | 2013-04-16 | 2015-12-02 | 豪夫迈·罗氏有限公司 | 帕妥珠单抗变体及其评估 |
US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
US10519247B2 (en) * | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
CA2944895A1 (en) | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Anti-her3 antibodies binding to the beta-hairpin of her3 |
EP3143049B1 (en) | 2014-05-14 | 2019-08-21 | F. Hoffmann-La Roche AG | Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2 |
CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
WO2017100642A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
CA3011949A1 (en) | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
KR101923641B1 (ko) * | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
TW202039567A (zh) | 2018-12-21 | 2020-11-01 | 瑞士商赫孚孟拉羅股份公司 | 靶向腫瘤之促效cd28抗原結合分子 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
ES2274537T5 (es) * | 1996-03-27 | 2015-09-14 | Genentech, Inc. | Anticuerpos ErbB3 |
ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
US7744882B2 (en) * | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7919098B2 (en) | 2002-03-26 | 2011-04-05 | Zensun ( Shanghai ) Sci & Tech Co., Ltd. | ErbB-3 based methods and compositions for treating neoplasms |
EP2248892B1 (en) | 2003-01-22 | 2015-04-22 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
WO2005011735A1 (en) | 2003-07-29 | 2005-02-10 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
WO2005018572A2 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
WO2005027966A2 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
KR20070050951A (ko) | 2004-09-08 | 2007-05-16 | 제넨테크, 인크. | 사멸 수용체 리간드 및 cd20 항체의 사용 방법 |
CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
WO2006114700A2 (en) | 2005-04-26 | 2006-11-02 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
BRPI0615397B1 (pt) | 2005-08-26 | 2023-10-03 | Roche Glycart Ag | Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2097754B2 (en) | 2006-11-28 | 2018-01-24 | Daiichi Sankyo Europe GmbH | Activated her3 as a marker for predicting therapeutic efficacy |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
PL2129396T3 (pl) * | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
EP2138511A1 (en) | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
BRPI0917871A2 (pt) | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
US8349574B2 (en) | 2009-01-15 | 2013-01-08 | Laboratory Corporation Of America Holdings | Methods of determining patient response by measurement of Her-3 |
MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
PE20120550A1 (es) | 2009-04-07 | 2012-05-21 | Roche Glycart Ag | ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET |
WO2010127181A1 (en) | 2009-04-29 | 2010-11-04 | Trellis Bioscience, Inc. | Improved antibodies immunoreactive with heregulin-coupled her3 |
MX336091B (es) | 2009-08-21 | 2016-01-08 | Merrimack Pharmaceuticals Inc | Anticuerpos contra el extodominio de erbb3 y usos de los mismos. |
JP2013507378A (ja) | 2009-10-09 | 2013-03-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗her3抗体の製造、特徴づけ及びその用途 |
US10208128B2 (en) | 2009-11-04 | 2019-02-19 | Affibody Ab | HER3 binding polypeptides |
JP5931736B2 (ja) | 2009-11-13 | 2016-06-08 | ウー3・フアルマ・ゲー・エム・ベー・ハーU3 Pharma | Her−3関連疾患を治療または予防するための物質および方法 |
KR20120098911A (ko) * | 2009-12-22 | 2012-09-05 | 로슈 글리카트 아게 | 항-her3 항체 및 이의 용도 |
EP2859893A1 (en) | 2010-03-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
ES2566602T3 (es) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
US20120156130A1 (en) | 2010-08-06 | 2012-06-21 | Thore Hettmann | Use of her3 binding agents in prostate treatment |
SI2606070T1 (sl) | 2010-08-20 | 2017-04-26 | Novartis Ag | Protitelesa za receptor 3 epidermalnega rastnega faktorja (HER3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CA2811747A1 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her3 antibodies |
CA2813796C (en) | 2010-10-18 | 2019-01-15 | Mediapharma S.R.L. | Erbb3 binding antibody |
US9155802B2 (en) * | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
ES2692379T3 (es) | 2010-11-01 | 2018-12-03 | Symphogen A/S | Anticuerpos anti-HER3 y composiciones |
ITRM20100577A1 (it) | 2010-11-02 | 2012-05-03 | Takis Srl | Immunoterapia contro il recettore erbb-3 |
ES2694153T3 (es) | 2011-09-30 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 y usos de los mismos |
-
2010
- 2010-12-17 KR KR1020127019170A patent/KR20120098911A/ko not_active IP Right Cessation
- 2010-12-17 US US12/971,300 patent/US8859737B2/en active Active
- 2010-12-17 PE PE2012000881A patent/PE20121616A1/es not_active Application Discontinuation
- 2010-12-17 MA MA35018A patent/MA33892B1/fr unknown
- 2010-12-17 SG SG2012046587A patent/SG181894A1/en unknown
- 2010-12-17 CN CN201080064271.3A patent/CN102822201B/zh active Active
- 2010-12-17 PL PL10798541T patent/PL2516469T3/pl unknown
- 2010-12-17 KR KR20147029079A patent/KR20140130751A/ko not_active Application Discontinuation
- 2010-12-17 JP JP2012545255A patent/JP5680671B2/ja active Active
- 2010-12-17 ES ES10798541T patent/ES2571226T3/es active Active
- 2010-12-17 MX MX2012007340A patent/MX2012007340A/es active IP Right Grant
- 2010-12-17 EP EP10798541.8A patent/EP2516469B1/en active Active
- 2010-12-17 BR BR112012015255A patent/BR112012015255A2/pt not_active IP Right Cessation
- 2010-12-17 MY MYPI2012002818A patent/MY161909A/en unknown
- 2010-12-17 AU AU2010335282A patent/AU2010335282B2/en not_active Ceased
- 2010-12-17 UA UAA201208617A patent/UA107821C2/uk unknown
- 2010-12-17 HU HUE10798541A patent/HUE029026T2/en unknown
- 2010-12-17 RS RS20160292A patent/RS54795B1/sr unknown
- 2010-12-17 WO PCT/EP2010/070062 patent/WO2011076683A1/en active Application Filing
- 2010-12-17 CA CA2782571A patent/CA2782571C/en not_active Expired - Fee Related
- 2010-12-17 DK DK10798541.8T patent/DK2516469T3/en active
- 2010-12-17 SI SI201031158A patent/SI2516469T1/sl unknown
- 2010-12-17 NZ NZ600262A patent/NZ600262A/xx not_active IP Right Cessation
- 2010-12-17 RU RU2012129735/10A patent/RU2560583C2/ru not_active IP Right Cessation
- 2010-12-20 AR ARP100104773A patent/AR079551A1/es unknown
- 2010-12-21 TW TW099145048A patent/TWI421092B/zh not_active IP Right Cessation
-
2012
- 2012-05-28 CR CR20120284A patent/CR20120284A/es unknown
- 2012-06-04 IL IL220162A patent/IL220162A/en not_active IP Right Cessation
- 2012-06-18 CL CL2012001649A patent/CL2012001649A1/es unknown
- 2012-06-21 EC ECSP12011995 patent/ECSP12011995A/es unknown
- 2012-06-27 CO CO12108245A patent/CO6551674A2/es active IP Right Grant
-
2013
- 2013-02-26 HK HK13102373.8A patent/HK1175183A1/xx not_active IP Right Cessation
-
2014
- 2014-09-08 US US14/480,192 patent/US20140377272A1/en not_active Abandoned
- 2014-09-08 US US14/480,198 patent/US9611331B2/en active Active
-
2015
- 2015-01-06 JP JP2015001019A patent/JP2015109848A/ja active Pending
-
2016
- 2016-05-13 CY CY20161100414T patent/CY1117563T1/el unknown
- 2016-06-24 HR HRP20160737TT patent/HRP20160737T1/hr unknown
-
2017
- 2017-02-17 US US15/436,267 patent/US10196456B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR079551A1 (es) | Anticuerpos anti-her3 y usos de los mismos | |
AR092487A2 (es) | Anticuerpos contra la angiopoyetina 2 humana | |
MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
BR112012004823A8 (pt) | Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica | |
BR112013021134A8 (pt) | Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico | |
CL2015002526A1 (es) | Anticuerpos anti-ox40 y métodos de uso de los mismos.(divisional de 545-13). | |
CL2013000074A1 (es) | Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos. | |
CL2011002943A1 (es) | Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica. | |
CL2012002416A1 (es) | Proteina de union capaz de unirse a dll4; construccion de anticuerpo que comprende dicha proteina; conjugado de anticuerpo; acido nucleico, vector y celula huesped que comprenden el anticuerpo; composicion para la liberacion de una proteina de union; metodo para reducir la actividad del dll4 humano. | |
BR112015012933A2 (pt) | proteínas de ligação ao antígeno bcma | |
BR112012020372A2 (pt) | "naticorpo que se liga ao csf- 1r humano, composição farmaceutica acido nucleico vetoresde expressão, célula hospedeira e método para a produção de um anticorpo recobinante | |
AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
CL2011000730A1 (es) | Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer. | |
CL2013000566A1 (es) | Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. | |
CL2013001831A1 (es) | Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos. | |
UY31904A (es) | Anticuerpos contra il-6 y sus usos | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
CL2012002662A1 (es) | Anticuerpos bivalentes biespecificos anti-veg y un segundo sitio de unión a antígeno que se une específicamente a ang-2 humana; composicion farmacéutica que comprende dicho anticuerpo; método de tratamiento de un paciente que sufre cancer; acido nucleico codificante de dicho anticuerpo, vector de expresión y célula huesped que contiene dicho ácido nucleico. | |
BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
CL2008002083A1 (es) | Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico | |
CR20120215A (es) | Anticuerpos contra csf-1r humano y usos de los mismos | |
AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
BR112012008173A2 (pt) | molécula de ligação específica de rsv | |
CL2010001425A1 (es) | Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |